Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation

Liver Transplantation

Volumn 19, Issue 7, 2013, Pages 690-700

  Pungpapong, Surakit ^a   Aqel, Bashar A ^b   Koning, Ludi ^c,d   Murphy, Jennifer L ^a   Henry, Tanisha M ^a   Ryland, Kristen L ^a   Yataco, Maria L ^a   Satyanarayana, Raj ^a   Rosser, Barry G ^a   Vargas, Hugo E ^b   Charlton, Michael R ^c   Keaveny, Andrew P ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BOCEPREVIR; CORTICOSTEROID; CYCLOSPORIN; ELTROMBOPAG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON ALPHA2A; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS; TELAPREVIR; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANORECTAL DISEASE; ANTIVIRAL THERAPY; ARTICLE; ASCITES; CARDIOVASCULAR DISEASE; CELLULITIS; CONTROLLED STUDY; CYTOPENIA; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIODONTAL ABSCESS; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RASH; REINFECTION; SINUSITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION;

AGED; ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84879551010     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23669     Document Type: Article

References (22)

1. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36 (suppl 1): S3-S20.
2. Wiesner RH, Sorrell M, Villamil F,; for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.
3. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120-1130.
4. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.
5. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599.
6. Berenguer M, Schuppan D,. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041.
7. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al.; for ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
8. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al.; for ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
9. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.; for SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
10. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al.; for REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
11. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.; for HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
12. Charlton M,. Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents-a potentially lethal cocktail. Hepatology 2011; 54: 3-5.
13. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X,. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27.
14. Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56: 1622-1630.
15. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP,. Telaprevir-based triple therapy in liver transplant recipients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470.
16. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20 (pt 1): 15-20.
17. Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience [abstract]. J Hepatol 2012; 56 (suppl 2): S21.
18. McCashland TM, Olivera-Martinez MA, Garcia-Saenz de Sicilia M, Mukherjee S, Rochling FA, Schafer DF, Sorrell MF,. Early experience with triple drug therapy (telaprevir, pegylated interferon α2A and ribavirin) in patients on cyclosporine A for hepatitis C recurrence after liver transplantation [abstract]. Liver Transpl 2012; 18 (suppl 1): S99.
19. Kwo PY, Ghabril M, Lacerda MA, Vinayek R, Fridell JA, Tector AJ, Vianna RM,. Use of telaprevir plus PEG interferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C [abstract]. Gastroenterology 2012; 142 (suppl 1): S934.
20. Mantry PS, Mubarak A, Weinstein JS, Madani B, Nazario HE, Mejia A, et al. Early virological response in patients with HCV recurrence after liver transplant treated with triple therapy: a single center experience [abstract]. Gastroenterology 2012; 142 (suppl 1): S931-S932.
21. Burton JR Jr, Everson GT,. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability [abstract]. Am J Transplant 2012; 12 (suppl 3): 188.
22. Sulkowski M, Roberts SK, Afdhal NH, Andreone P, Diago M, Pol S, et al. Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 studies [abstract]. Gastroenterology 2012; 142 (suppl 1): S919.